Malcolm J Low Selected Research

Pro-Opiomelanocortin (Proopiomelanocortin)

11/2021	Adult-born proopiomelanocortin neurons derived from Rax-expressing precursors mitigate the metabolic effects of congenital hypothalamic proopiomelanocortin deficiency.
3/2021	Mice lacking PC1/3 expression in POMC-expressing cells do not develop obesity.
1/2020	Hypothalamic POMC deficiency increases circulating adiponectin despite obesity.
1/2020	Expression of a hypomorphic Pomc allele alters leptin dynamics during late pregnancy.
1/2020	The transcriptional regulator PRDM12 is critical for Pomc expression in the mouse hypothalamus and controlling food intake, adiposity, and body weight.
3/2019	Selective Restoration of Pomc Expression in Glutamatergic POMC Neurons: Evidence for a Dynamic Hypothalamic Neurotransmitter Network.
1/2019	Hypothalamic POMC or MC4R deficiency impairs counterregulatory responses to hypoglycemia in mice.
1/2019	The Homeodomain Transcription Factor NKX2.1 Is Essential for the Early Specification of Melanocortin Neuron Identity and Activates Pomc Expression in the Developing Hypothalamus.
1/2018	17α-estradiol acts through hypothalamic pro-opiomelanocortin expressing neurons to reduce feeding behavior.
1/2018	Hypothalamic ER-associated degradation regulates POMC maturation, feeding, and age-associated obesity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Malcolm J Low Research Topics

Disease

28	Obesity 11/2021 - 07/2002
13	Body Weight (Weight, Body) 03/2021 - 05/2003
9	Hyperphagia (Overeating) 01/2020 - 04/2005
8	AIDS-Related Complex (ARC) 01/2020 - 06/2003
7	Morbid Obesity 01/2019 - 04/2005
6	Insulin Resistance 11/2021 - 02/2006
4	Prolactinoma (Prolactinomas) 01/2006 - 10/2002
3	Neoplasms (Cancer) 12/2017 - 02/2003
3	Anorexia 08/2011 - 07/2002
2	Hyperplasia 12/2017 - 01/2006
2	Glycosuria 10/2017 - 03/2016
2	Hyperglycemia 03/2016 - 11/2012
2	Hyperprolactinemia 01/2006 - 12/2002
2	Infections 12/2004 - 10/2003
2	Gastritis 12/2004 - 10/2003
2	Pituitary Neoplasms (Pituitary Adenoma) 02/2003 - 01/2002
1	Proopiomelanocortin Deficiency 11/2021
1	Body Weight Changes 01/2020
1	Hypoadiponectinemia 01/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019
1	Hypoglycemia (Reactive Hypoglycemia) 01/2019
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2019
1	Alcoholism (Alcohol Abuse) 01/2018
1	Multiple Endocrine Neoplasia Type 1 12/2017
1	Gastrinoma 12/2017
1	Weight Loss (Weight Reduction) 10/2017
1	Type 2 Diabetes Mellitus (MODY) 10/2017
1	Hypertension (High Blood Pressure) 04/2015
1	Overweight 11/2012
1	Hyperinsulinism (Hyperinsulinemia) 11/2012
1	Pain (Aches) 06/2011
1	Substance-Related Disorders (Drug Abuse) 07/2009
1	Schizophrenia (Dementia Praecox) 10/2008
1	Cognitive Dysfunction 10/2008
1	Adenoma (Adenomas) 02/2007
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 02/2007
1	Hypertrophy 02/2007
1	Weight Gain 02/2006
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2006
1	Diarrhea 12/2004
1	Hemorrhage 12/2004
1	Portal Hypertension 12/2004

Drug/Important Bio-Agent (IBA)

33	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 11/2021 - 06/2003
9	MelanocortinsIBA 01/2020 - 07/2002
9	Peptides (Polypeptides)IBA 01/2020 - 01/2002
5	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 03/2016
5	Hormones (Hormone)IBA 01/2019 - 02/2003
4	Melanocyte-Stimulating Hormones (MSH)IBA 03/2021 - 01/2006
4	Serotonin (5 Hydroxytryptamine)IBA 10/2017 - 06/2003
3	LeptinIBA 01/2020 - 10/2016
3	Messenger RNA (mRNA)IBA 03/2019 - 02/2003
3	Pharmaceutical PreparationsIBA 01/2019 - 07/2009
3	Dopamine (Intropin)FDA LinkGeneric 01/2006 - 10/2002
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 12/2004 - 01/2002
2	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 03/2021 - 11/2019
2	Adrenocorticotropic Hormone (ACTH)FDA Link 03/2021 - 02/2007
2	melanotan-IIIBA 01/2020 - 03/2016
2	NeuropeptidesIBA 01/2019 - 04/2015
2	Epinephrine (Adrenaline)FDA LinkGeneric 01/2019 - 03/2016
2	GastrinsIBA 12/2017 - 10/2003
2	lorcaserinIBA 10/2017 - 10/2014
2	Appetite Depressants (Anorectics)IBA 10/2014 - 06/2003
2	CorticosteroneIBA 02/2007 - 02/2006
2	GlucocorticoidsIBA 02/2007 - 02/2006
2	Dopamine Receptors (Dopamine Receptor)IBA 01/2006 - 12/2002
2	Estrogens (Estrogen)FDA Link 02/2003 - 12/2002
1	EnzymesIBA 03/2021
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	AdiponectinIBA 01/2020
1	Leptin ReceptorsIBA 01/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Glucagon (Glukagon)FDA Link 01/2019
1	Cocaine (Cocaine HCl)IBA 01/2019
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 01/2019
1	Naltrexone (ReVia)FDA LinkGeneric 01/2019
1	Bupropion (Wellbutrin)FDA LinkGeneric 01/2019
1	Streptozocin (Streptozotocin)FDA Link 01/2019
1	Transcription Factors (Transcription Factor)IBA 01/2019
1	Cysteine (L-Cysteine)FDA Link 01/2018
1	1- (5- chloro- 1- ((2,4- dimethoxyphenyl)sulfonyl)- 3- (2- methoxyphenyl)- 2- oxo- 2,3- dihydro- 1H- indol- 3- yl)- 4- hydroxy- N,N- dimethyl- 2- pyrrolidinecarboxamideIBA 01/2018
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2018
1	Nuclear Proteins (Protein, Nuclear)IBA 12/2017
1	Tamoxifen FDA LinkGeneric 10/2016
1	Insulin (Novolin)FDA Link 03/2016
1	Melanocortin Receptors (Melanocortin Receptor)IBA 03/2016
1	Blood Glucose (Blood Sugar)IBA 03/2016
1	CatecholaminesIBA 03/2016
1	Sodium-Glucose Transport ProteinsIBA 03/2016
1	sibutramine (Meridia)FDA Link 10/2014
1	FenfluramineIBA 10/2014
1	Nicotine FDA Link 08/2011
1	Drinking WaterIBA 02/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2006
1	ProlactinIBA 01/2006
1	Cytotoxins (Cytolysins)IBA 12/2004

Therapy/Procedure

3	Therapeutics 01/2019 - 12/2004
2	Drug Therapy (Chemotherapy) 01/2019 - 10/2014
1	Glycemic Control 10/2017
1	Denervation 10/2017